Overview

pyrimethamine


'pyrimethamine' can also refer to...

pyrimethamine

pyrimethamine

pyrimethamine n.

pyrimethamine n.

pyrimethamine n.

pyrimethamine n.

Indigenous evolution of Plasmodium falciparum pyrimethamine resistance multiple times in Africa

Methotrexate Is Highly Potent Against Pyrimethamine-Resistant Plasmodium vivax

Rapid Selection of Plasmodium falcipavum Dihydrofolate Reductase Mutants by Pyrimethamine Prophylaxis

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

Parasitological Rebound Effect and Emergence of Pyrimethamine Resistance in Plasmodium falciparum after Single-Dose Sulfadoxine-Pyrimethamine

Pyrimethamine-Clindamycin vs. Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients with AIDS

Determinants of Treatment Response to Sulfadoxine-Pyrimethamine and Subsequent Transmission Potential in Falciparum Malaria

Resistance to chloroquine and sulfadoxine-pyrimethamine in Plasmodium falciparum in Muheza district, Tanzania

Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan

Efficacy of combined chloroquine and sulfadoxine–pyrimethamine in uncomplicated Plasmodium falciparum malaria in Bangladesh

Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children

Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania

Case report: Life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug

 

More Like This

Show all results sharing this subject:

  • Clinical Pharmacology and Therapeutics

GO

Show Summary Details

Quick Reference

An antimalarial drug used together with sulphonamide to treat falciparum malaria and with sulfadiazine to treat toxoplasmosis.

Subjects: Clinical Pharmacology and Therapeutics.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.